XML 77 R67.htm IDEA: XBRL DOCUMENT v3.25.3
Expenses - Summary of expenses (Detail) - AUD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Loss before income tax includes the following specific      
Scientific Advisory Board costs $ 0 $ 0 $ 31
Employee benefits expense- salaries & wages and staff benefits 1,761 2,161 2,250
Employee benefits expense- superannuation 34 36 29
Employee benefits expense- share based payments 172 485 702
Total research & development expense (excluding amortisation) 6,391 15,511 13,695
Amortisation 934 1,869 1,869
Total research & development expense 7,325 17,380 15,564
Net foreign exchange loss/(gain) 310 (20) 46
Expense relating to short term lease 59 124 152
Defined contribution superannuation expense 54 88 131
Employee benefits expense G&A      
- salaries & wages and staff benefits 1,062 486 1,467
- superannuation 20 52 102
- share based payments 481 48 457
Total employee benefits expense G&A 1,563 586 2,026
EVT-801 program costs [member]      
Loss before income tax includes the following specific      
Research and development expense 1,391 5,277 5,060
Cantrixil program costs [member]      
Loss before income tax includes the following specific      
Research and development expense 2 1 5
Paxalisib program costs [member]      
Loss before income tax includes the following specific      
Research and development expense 3,031 7,551 5,618
Paxalisib licensing agreement [member]      
Loss before income tax includes the following specific      
Amortisation 542 1,084 1,084
Evotec Licensing Agreement [member]      
Loss before income tax includes the following specific      
Amortisation $ 392 $ 785 $ 785